Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells

Anderson, 1999, Radiometal-labeled agents (non-technetium) for diagnostic imaging, Chem. Rev., 99, 2219, 10.1021/cr980451q

Baidoo, 1998, Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues, Bioconjugate Chem., 9, 218, 10.1021/bc9701959

Bakker, 1991, [Indium-111-DTPA-D-Phe-1]octreotide, a potential radiopharmaceutical for imaging somatostatin receptor positive tumors, Life Sci., 49, 1583, 10.1016/0024-3205(91)90052-D

Behr, 1996, Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides?, J. Nucl. Med., 37, 834

Bijsterbosch, 1995, Selective drug delivery by means of receptor-mediated endocytosis, Q. J. Nucl. Med., 39, 4

Boerman, 2000, Radio-labeled receptor-binding peptides, Sem. Nucl. Med., 30, 195, 10.1053/snuc.2000.7441

Brechbiel, 1986, Synthesis of 1-(p-Isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies, Inorg. Chem., 25, 2772, 10.1021/ic00236a024

Breeman, 1999, Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]Bombesin, a new radioligand for bombesin-receptor scintigraphy, Int. J. Cancer, 83, 657, 10.1002/(SICI)1097-0215(19991126)83:5<657::AID-IJC15>3.0.CO;2-Y

Breeman, 1999, Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy, Int. J. Cancer, 81, 658, 10.1002/(SICI)1097-0215(19990517)81:4<658::AID-IJC24>3.0.CO;2-P

Caravan, 1999, Gadolinium(III) chelates as MRI contrast agents, Chem. Rev., 99, 2293, 10.1021/cr980440x

Cutler, 2000, Current and potential therapeutic uses of lanthanide radioisotopes, Cancer Biotherapy & Radiopharm., 15, 531, 10.1089/cbr.2000.15.531

deJong, 1997, Yttrium-90 and Indium-111 labeling, receptor binding, and biodistribution of [DOTA0-D-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy, Eur. J. Nucl. Med., 24, 368, 10.1007/s002590050064

Eckelman, 1993, The design of site-directed radiopharmaceuticals for use in drug discovery

Gali, 2000, In vitro and in vivo evaluation of 111In-labeled DOTA-8-Aoc-BBN[7-14]NH2 conjugate for specific targeting of tumors expressing gastrin releasing peptide receptors (GRP-R), J. Nucl. Med., 41, 119

Giblin, 1998, Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination, Proc. Natl. Acad. Sci. U. S. A., 95, 12814, 10.1073/pnas.95.22.12814

Heeg, 1999, The role of inorganic chemistry in the development of radiometal agents for cancer therapy, Acc. Chem. Res., 32, 1050, 10.1021/ar980002c

Hoffman, 2001, J. Nucl. Med.

Hoffman, 1997, Synthesis and characterization of 105Rh labeled bombesin analogues, J. Labelled Compd. Radiopharm., 40, 490

Hoffman, 2001, Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells, Nucl. Med. Biol., 28, 527, 10.1016/S0969-8051(01)00209-8

Hom, 1997, Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals, Nucl. Med. Biol., 24, 485, 10.1016/S0969-8051(97)00066-8

Karra, 1999, 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent, Bioconjugate Chem., 10, 254, 10.1021/bc980096a

Kvols, 1999, Somatostatin receptor imaging of neuroendocrine carcinomas, 153

Kwekkeboom, 2001, [177Lu-DOTA0,Tyr3]octreotate, Eur. J. Nucl. Med., 28, 1319, 10.1007/s002590100574

Lewis, 2001, Toxicity and dosimetry of 177Lu-DOTA-Y3-Octreotate in a rat model, Int. J. Cancer, 94, 873, 10.1002/ijc.1540

Mahmoud, 1985, [Psi13,14] bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo, Life Sci., 37, 105

Markwalder, 1999, Gastrin-releasing peptide receptors in the human prostate, Cancer Res, 59, 1152

Ning, 1995, Pharmacokinetic studies of 105Rh(III) Complexes with macrocycles, J. Labelled Compd. Radiopharm., 37, 426

Press, 1994, Radiolabeled antibody therapy of lymphomas, Biol. Ther. Cancer Update, 4, 1

Qin, 1994, Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro, Cancer Res., 54, 1035

Qin, 1995, Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP, Int. J. Cancer, 63, 257, 10.1002/ijc.2910630219

Rogers, 1999, In vitro binding and internalization of an Indium-111 labeled bombesin derivative to cells expressing the gastrin releasing peptide receptor, 519

Rogers, 1997, Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector, Cancer Suppl., 8, 2419, 10.1002/(SICI)1097-0142(19971215)80:12+<2419::AID-CNCR13>3.0.CO;2-F

Seregni, 1998, Radionuclide imaging of neuroendocrine tumors, Eur. J. Nucl. Med., 25, 639, 10.1007/s002590050267

Schubiger, 1996, Vehicles, chelators, and radionuclides, Bioconjugate Chem., 7, 165, 10.1021/bc950097s

Smith, 2001, Radiochemical investigations of 99mTc-N3S-X-BBN[7-14]NH2, Bioconjugate Chem.

Smith, 2001, Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2, J. Labelled Compd. Radiopharm., 44, 706, 10.1002/jlcr.25804401249

Stein, 2001, Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7, J. Nucl. Med., 42, 967

Ugur, 1996, Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma, Nucl. Med. Biol., 23, 1, 10.1016/0969-8051(95)02001-2

Van de Wiele, 2000, 99mTc-RP-527, a gastrin releasing peptide (GRP) analogue for visualization of GRP receptor expressing malignancies, Nucl. Med. Commun., 21, 21

Van de Wiele, 2000, Technetium-99m RP525, a GRP analogue for visualization of GRP receptor-expressing malignancies, Eur. J. Nucl. Med., 27, 1694, 10.1007/s002590000355

Volkert, 1999, Therapeutic radiopharmaceuticals, Chem. Rev., 99, 2269, 10.1021/cr9804386